Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to Hold at Zacks Research

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Wednesday, Zacks reports.

Other equities analysts have also issued reports about the stock. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $47.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday. Argus upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Finally, Oppenheimer lifted their target price on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 9th. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $48.64.

Get Our Latest Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Trading Down 8.8%

NYSE:TEVA opened at $38.53 on Wednesday. The firm has a market cap of $44.90 billion, a P/E ratio of 89.61, a PEG ratio of 3.66 and a beta of 0.97. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The stock’s 50 day simple moving average is $40.56 and its 200-day simple moving average is $35.22. Teva Pharmaceutical Industries has a 12-month low of $24.01 and a 12-month high of $44.57.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities analysts anticipate that Teva Pharmaceutical Industries will post 1.98 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 25,000 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $42.91, for a total value of $1,072,750.00. Following the completion of the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $2,392,447.05. This trade represents a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Savage sold 7,342 shares of the business’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider owned 8,500 shares in the company, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 715,945 shares of company stock valued at $29,061,351 in the last three months. Insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC increased its holdings in Teva Pharmaceutical Industries by 16.6% in the third quarter. Kestra Advisory Services LLC now owns 53,716 shares of the company’s stock valued at $2,127,000 after buying an additional 7,631 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $1,302,000. Integrated Wealth Concepts LLC boosted its stake in shares of Teva Pharmaceutical Industries by 68.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,780 shares of the company’s stock worth $783,000 after acquiring an additional 8,063 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Teva Pharmaceutical Industries by 150.9% in the 3rd quarter. Allworth Financial LP now owns 3,202 shares of the company’s stock worth $127,000 after acquiring an additional 1,926 shares during the period. Finally, Quantessence Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $734,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Latest Teva Pharmaceutical Industries News

Investors following TEVA have been watching these news items:

  • Positive Sentiment: Barclays raised its price target to $50 from $47 and maintained an Overweight rating. Argus also raised its target to $50 and reaffirmed a Buy rating, while HC Wainwright maintained its Buy rating. Barclays analyst action Argus forecast HC Wainwright rating
  • Neutral Sentiment: Teva said its R&D strategy, priorities and commitments remain unchanged, including its goal of $6–7 billion in innovative-medicines revenue by 2030. David Gardiner will lead the transition while the company searches for a permanent successor. Teva leadership announcement
  • Negative Sentiment: Executive Vice President of Global R&D and Chief Medical Officer Eric Hughes is leaving for an opportunity outside Teva. His departure may unsettle investors given the importance of R&D execution to the company’s growth strategy, despite his planned support during the transition. R&D leadership transition report

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Further Reading

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.